Iqvia Holdings is a global leader in advancing healthcare by providing data analytics, technology, and consulting services to the pharmaceutical and life sciences industries. The company specializes in helping organizations improve their clinical trials, optimize research and development processes, and enhance patient engagement. By leveraging its extensive data assets and innovative technology platforms, Iqvia aids clients in making informed decisions that drive efficiency and effectiveness in bringing new therapies to market. Read More
Clinical research company IQVIA (NYSE: IQV) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 8.7% year on year to $4.37 billi...
IQVIA (NYSE:IQV) reported second-quarter results that exceeded the high end of its guidance, supported by accelerating organic revenue growth, higher R&D Solutions bookings and operational productivity gains. The company also raised its full-year outlook for revenue, adjusted EBITDA and adjusted dil
What Happened? Shares of clinical research company IQVIA (NYSE: IQV) jumped 12.9% in the morning session after the company reported second-quarter results th...
Clinical research company IQVIA (NYSE: IQV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.7% year on year to $4.37 billion. The compa...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended June 30, 2026.
Clinical research company IQVIA (NYSE: IQV) will be reporting earnings this Tuesday before market hours. Here’s what you need to know. IQVIA beat analysts’ r...
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, shared recommendations for strengthening the United States as a leading destination for early clinical development during the U.S. House Committee on Energy and Commerce Subcommittee on Health hearing, “Maintaining America’s Leadership in Biomedical Innovation: FDA’s Role in Advancing U.S. Drug Development.”
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its second-quarter 2026 financial results before the market opens on Tuesday, July 28, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at: http://ir.iqvia.com.
What Happened? Shares of clinical research company IQVIA (NYSE: IQV) jumped 5.8% in the afternoon session after Baird raised its price target on the stock to...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-...
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...
Over the last six months, IQVIA’s shares have sunk to $177.52, producing a disappointing 19.8% loss - a stark contrast to the S&P 500’s 12.4% gain. This migh...
Wiley (NYSE: WLY) and IQVIA (NYSE: IQV) today released Scientific Discovery & AI: The Science-to-Patient Journey, a cross-sector intelligence report drawing on candid dialogue among more than 25 senior leaders from pharma R&D, academic medicine, health systems, AI and technology, publishing and learned societies.
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
